国金证券股份有限公司 关于新亚强硅化学股份有限公司 首次公开发行限售股上市流通的核查意见 国金证券股份有限公司（以下简称"国金证券"、"保荐机构"）作为新亚强 硅化学股份有限公司（以下简称"新亚强"或"公司"）首次公开发行股票并在 上海证券交易所主板上市的保荐机构，根据《证券发行上市保荐业务管理办法》、 《上海证券交易所股票上市规则》、《上海证券交易所上市公司自律监管指引第 1 号—规范运作》、《上海证券交易所上市公司自律监管指引第 11 号—持续督导》 等有关规定，就新亚强首次公开发行限售股上市流通的事项进行了审慎核查，发 表核查意见如下： 一、本次限售股上市类型 经中国证券监督管理委员会《关于核准新亚强硅化学股份有限公司首次公开 发行股票的批复》（证监许可[2020]1589 号）核准，并经上海证券交易所同意， 新亚强硅化学股份有限公司（以下简称"公司"）首次公开发行人民币普通股（A 股）股票 38,890,000 股，并于 2020 年 9 月 1 日在上海证券交易所挂牌上市。 本次上市流通的限售股为公司首次公开发行的限售股，涉及初琳、红塔创新 （昆山）创业投资有限公司、红塔创新投资股份有限公司、孙秀杰 ...

证券代码：603155 证券简称：新亚强 公告编号：2023-044 新亚强硅化学股份有限公司 本次股票上市类型为首发股份；股票认购方式为网下，上市股数为 169,171,500 股。 本次股票上市流通总数为 169,171,500 股。 本次股票上市流通日期为 2023 年 9 月 1 日。 一、本次限售股上市类型 经中国证券监督管理委员会《关于核准新亚强硅化学股份有限公司首次公开 发行股票的批复》（证监许可[2020]1589 号）核准，并经上海证券交易所同意，新 亚强硅化学股份有限公司（以下简称"公司"）首次公开发行人民币普通股（A 股） 股票 38,890,000 股，并于 2020 年 9 月 1 日在上海证券交易所挂牌上市。 本次上市流通的限售股为公司首次公开发行的限售股，涉及初琳、红塔创新 （昆山）创业投资有限公司、红塔创新投资股份有限公司、孙秀杰、初亚军、宿迁 亚强智盈企业管理中心（有限合伙）共计 6 名股东，限售期自公司首次公开发行股 票上市之日起 36 个月。 关于首次公开发行限售股上市流通的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥392,222,444.87, a decrease of 41.05% compared to ¥665,368,135.42 in the same period last year[23]. - The net profit attributable to shareholders for the first half of 2023 was ¥102,041,714.38, down 46.61% from ¥191,120,801.78 in the previous year[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥90,004,858.20, a decline of 49.86% compared to ¥179,524,620.74 in the same period last year[23]. - The basic earnings per share for the first half of 2023 was ¥0.45, a decrease of 47.06% from ¥0.85 in the same period last year[24]. - The total assets at the end of the reporting period were ¥2,557,537,813.06, down 5.46% from ¥2,705,163,828.54 at the end of the previous year[23]. - The net assets attributable to shareholders at the end of the reporting period were ¥2,224,331,918.53, a decrease of 5.21% from ¥2,346,594,919.64 at the end of the previous year[23]. - The weighted average return on net assets for the first half of 2023 was 4.32%, a decrease of 4.20 percentage points from 8.52% in the same period last year[24]. - The net cash flow from operating activities was ¥149,832,766.42, down 22.47% from ¥193,256,420.35 in the previous year[23]. Research and Development - The company specializes in the research, production, and sales of silicone fine chemicals, classified under "C26 Chemical Raw Materials and Chemical Products Manufacturing" according to industry standards[30]. - The company has developed a patented technology for hexamethyldisilazane, achieving high purity and low impurities, meeting semiconductor industry quality requirements[33]. - The company has established a long-term partnership with universities for R&D, resulting in 52 patents and recognition of its hexamethyldisilazane product as a champion product in the manufacturing sector[34]. - The company has made significant progress in R&D, with breakthroughs in products such as phenyl silicone resin and electronic-grade hexamethyldisilazane, enhancing product quality to meet semiconductor industry demands[38]. - The company focuses on R&D for high-value-added organic silicon products, but acknowledges the risks associated with long development cycles and market acceptance of new products[53]. Market and Competitive Position - The company experienced a significant decline in product sales and prices due to the economic environment, impacting revenue and profit margins[25]. - The company has achieved a leading market share in its niche, recognized by major international silicone manufacturers and pharmaceutical companies[33]. - The company is focusing on expanding its market presence in high-end new materials and electronic chemicals, with a strengthened professional service capability[38]. - The company operates in a highly competitive organic silicon industry, facing risks from market expansion and potential price declines due to increased competition from both domestic and international players[50]. Environmental and Safety Measures - The company emphasizes the importance of safety in production, having achieved a secondary certification for safety production standards, but acknowledges the inherent risks associated with handling hazardous chemicals[51]. - Environmental protection measures are in place, including ISO 14001:2015 certification, but the company may face increased costs and regulatory challenges due to stricter environmental standards in the future[52]. - The company has established a wastewater treatment system utilizing MVR evaporation and biochemical treatment processes, ensuring compliance with discharge standards[61]. - The company has implemented measures to reduce carbon emissions, expecting to decrease CO2 equivalent emissions by 2,104 tons[67]. Shareholder and Management Information - The company has not proposed any profit distribution plan or capital reserve transfer to increase share capital for the reporting period[6]. - The company has appointed a new deputy general manager, Pan Yining, to enhance management capabilities[57]. - The company commits to not transferring or entrusting the management of shares held before the IPO for 36 months post-listing[73]. - Major shareholders must announce their reduction plans 15 trading days in advance and cannot reduce shares without following this procedure[74]. - The company will not repurchase shares held before the IPO during the lock-up period[79]. Financial Position and Assets - The company's total liabilities decreased to ¥303,451,551.34 from ¥328,650,563.02, showing a reduction of about 7.7%[112]. - The total equity attributable to shareholders decreased to ¥2,224,331,918.53 from ¥2,346,594,919.64, reflecting a decline of approximately 5.2%[112]. - The company's inventory decreased to ¥167,152,543.44 from ¥189,522,732.91, indicating a reduction of about 11.8%[110]. - The accounts receivable increased to ¥105,235,995.22 from ¥93,467,397.21, showing an increase of approximately 12.5%[110]. - The company's fixed assets increased to ¥381,058,242.40 from ¥341,478,378.02, reflecting an increase of about 11.6%[111]. Future Outlook - The company plans to expand its market presence and invest in new product development to drive future growth[140]. - The management remains optimistic about future growth prospects, focusing on innovation and market expansion strategies[150]. - The future outlook remains positive, with management guiding for continued revenue growth and improved profitability in the upcoming quarters[140].

证券代码：603155 证券简称：新亚强 公告编号：2023-042 新亚强硅化学股份有限公司 关于公司 2023 年半度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 经中国证券监督管理委员会《关于核准新亚强硅化学股份有限公司首次公开 发行股票的批复》（证监许可[2020]1589 号）核准，公司于上海证券交易所向社 会公众公开发行人民币普通股（A 股）股票 3,889 万股，每股面值为人民币 1.00 元，每股发行价格为人民币 31.85 元，募集资金总额为人民币 1,238,646,500.00 元，扣除与本 次发 行相关的费用 38,646,500.00 元后，募集 资金净额为 1,200,000,000.00 元，上述资金于 2020 年 8 月 26 日全部到账。瑞华会计师事务 所（特殊普通合伙）对募集资金到账情况进了审验，并出具了瑞华验字 [2020]91010001 号《验资报告》。 （二）募集资金使用金额及当前余 ...

证券代码：603155 证券简称：新亚强 公告编号：2023-039 新亚强硅化学股份有限公司 第三届董事会第十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 新亚强硅化学股份有限公司（以下简称"公司"）第三届董事会第十次会议 通知于 2023 年 8 月 11 日以电子邮件及专人送达的方式发出，会议于 2023 年 8 月 22 日在公司会议室以现场和通讯相结合的方式召开。本次会议应出席董事 6 人，实际出席董事 6 人，会议由董事长初亚军先生主持，公司监事及部分高级管 理人员列席会议。本次会议的召集、召开符合《公司法》等有关法律、法规及《公 司章程》的规定。 二、董事会会议审议情况 （一）审议通过了《关于 2023 年半年度报告及其摘要的议案》 一、董事会会议召开情况 表决结果：6 票同意；0 票反对；0 票弃权。 特此公告。 新亚强硅化学股份有限公司董事会 2022 年 8 月 23 日 具体内容详见公司于 2023 年 8 月 23 日披露于上海证券交易所网站上的 《2023 年半年报报告》《20 ...

证券代码：603155 证券简称：新亚强 公告编号：2023-043 新亚强硅化学股份有限公司 关于 2023 年半年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据《上海证券交易所上市公司自律监管指引第 3 号—行业信息披露》及相 关要求，新亚强硅化学股份有限公司（以下简称"公司"）现将 2023 年半年度 主要经营数据披露如下： 一、主要产品的产量、销量及收入实现情况 | 主要产品 | 2023 | 年 1-6 | 月产量 | 2023 年 | 1-6 | 月销量 | 2023 年 | 1-6 | 月销售金 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | （吨） | | （吨） | | | 额（万元） | | | | 功能性助剂 | | 4,314.20 | | 4,254.35 | | | 27,039.94 | | | | 苯基氯硅烷 | | 2,128.33 | | 1,264.44 | | | ...

二、监事会会议审议情况 （一）审议通过了《关于 2023 年半年度报告及其摘要的议案》 监事会认为：公司 2023 年半年度报告及摘要的编制和审议程序符合法律、 法规及《公司章程》的有关规定；2023 年半年度报告及摘要的内容和格式符合 中国证监会和上海证券交易所的各项规定，所包含的信息真实地反映报告期内的 经营和财务状况；未发现参与编制和审议的人员有违反保密规定的行为。 表决结果：3 票同意；0 票反对；0 票弃权。 证券代码：603155 证券简称：新亚强 公告编号：2023-040 新亚强硅化学股份有限公司 第三届监事会第十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 新亚强硅化学股份有限公司（以下简称"公司"）第三届监事会第十次会议 通知于 2023 年 8 月 11 日以电子邮件及专人送达的方式发出，会议于 2023 年 8 月 22 日在公司会议室以现场及通讯相结合方式召开。本次会议应出席监事 3 人， 实际出席监事 3 人，会议由监事会主席刘贤钊先生主持。本次会议的 ...

证券代码：603155 证券简称：新亚强 公告编号：2023-038 会议召开时间：2023 年 8 月 23 日(星期三) 14:00-15:00 新亚强硅化学股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会 议 召 开 地 点 ： 上海证券 交易所上证路演中心（ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 8 月 16 日(星期三) 至 8 月 22 日(星期二)16:00 前登录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公司邮箱 ir@newasiaman.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 新亚强硅化学股份有限公司（以下简称"公司"）将于 2023 年 8 月 23 日发 布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半 年 ...

2023 年第一季度报告 证券代码：603155 证券简称：新亚强 新亚强硅化学股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 1、公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2、公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财 务信息的真实、准确、完整。 3、第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 （一）主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | | 本报告期比上年同期增减 | | | --- | --- | --- | --- | --- | | | | | 变动幅度(%) | | | 营业收入 | | 226,715,678.12 | | -31.12 | | 归属于上市公司股东的净利润 | | 54,899,215.85 | | -42.59 | | 归属于上市公司股东的扣除非经常 ...

Financial Performance - The company's operating revenue for 2022 was CNY 1,133,598,652.44, representing a 28.82% increase compared to CNY 879,996,006.51 in 2021[22] - The net profit attributable to shareholders for 2022 was CNY 301,717,038.19, a decrease of 5.55% from CNY 319,444,551.13 in the previous year[22] - The net profit after deducting non-recurring gains and losses was CNY 284,406,514.11, down 2.39% from CNY 291,373,246.30 in 2021[22] - The net cash flow from operating activities increased by 57.50% to CNY 299,988,969.57, compared to CNY 190,468,110.19 in 2021[22] - The proposed cash dividend is CNY 10.00 per 10 shares, totaling CNY 225,562,000.00, along with a capital reserve conversion of 4 shares for every 10 shares held[6] - The company achieved significant production efficiency improvements and product quality enhancements through ongoing process optimization and technological innovation[34] - The company achieved operating revenue of CNY 1,133,598,652.44, an increase of 28.82% compared to the previous year[43] - Operating costs rose to CNY 785,392,756.44, reflecting a significant increase of 56.39% year-on-year, primarily due to rising raw material prices and increased production volume[45] - The company’s total assets reached CNY 2,705,163,800, a 7.97% increase from the previous year, and net assets attributable to shareholders increased by 6.64% to CNY 2,346,594,900[43] Research and Development - Research and development expenses increased by 30.89% to CNY 36,856,352.18, indicating a commitment to innovation and product development[44] - The company has established a long-term partnership with universities and research institutions, enhancing its R&D capabilities and innovation potential[41] - The company is focusing on R&D innovation to maintain its competitive edge in the organic silicon market[68] - The Shanghai R&D center has entered the installation and commissioning phase, while project design work at the Hubei facility is progressing smoothly[33] Market Expansion and Strategy - The company is actively expanding into new markets such as new energy vehicles, pharmaceuticals, and electronics, leveraging its core products' leading position in niche markets[33] - The company is accelerating the construction of projects, including a 10,000-ton annual production capacity for phenyl chlorosilane and a 2,500-ton annual production capacity for phenyl intermediates[34] - The company is optimizing its product line to meet the growing market demand in sectors such as organic silicon new materials, pharmaceuticals, and electronic chemicals[80] - The company is exploring potential mergers and acquisitions to strengthen its market position[175] Governance and Compliance - The company has established a governance structure that includes a general meeting of shareholders, a board of directors, a supervisory board, and management, ensuring clear responsibilities and checks and balances among these entities[95] - The board of directors consists of 6 members, with 3 independent directors, meeting the legal requirements and ensuring fair and effective decision-making[97] - The company has strengthened its information disclosure management, ensuring timely and accurate communication of relevant information to all shareholders[98] - The company has not faced any requests for a temporary shareholders' meeting from shareholders holding more than 10% of voting shares during the reporting period[95] Environmental and Safety Measures - The company emphasizes safety in its production processes, having achieved secondary certification for safety production standards, but acknowledges the inherent risks associated with handling hazardous chemicals[91] - Environmental protection measures are in place, including ISO 14001:2015 certification, but the company may face increased costs and regulatory challenges in the future[92] - The company invested approximately 27.99 million yuan in environmental protection during the reporting period[134] - The company has established a wastewater treatment system that complies with discharge standards, utilizing MVR evaporation and biochemical treatment processes[136] Shareholder Information - The total number of shares held by the top ten shareholders is 116,670,000, with significant increases in holdings for several key shareholders[199] - The largest shareholder, 初琳, holds 103,725,189 shares, representing 45.99% of the total shares[199] - The company plans to lift restrictions on shares for several shareholders on September 1, 2023[195] - The total number of ordinary shareholders increased from 13,137 to 14,151 during the reporting period[196] Financial Management - The company has engaged in entrusted financial management with a total amount of 220,951,000 RMB from self-owned funds and 178,000,000 RMB from raised funds[172] - The company has received returns from various entrusted financial management projects, with annualized yields ranging from 1.85% to 3.35%[172] - The company has maintained a good credit status with no defaults on court judgments or significant overdue debts[168] Risks and Challenges - The company faces risks from intensified market competition as domestic and international players expand their presence in the silicone market, potentially leading to price declines[90] - Macroeconomic fluctuations may impact the company's operations, as its business is closely tied to various downstream industries, which could affect customer demand[90]